Description

Inside Bio-Rad’s Digital PCR Bet — Why QX700 Could Redefine Its Long-Term Growth Trajectory!

Bio-Rad Laboratories reported a moderate financial performance for the fiscal year 2025, reflecting both achievements and challenges. The company’s revenue for the fourth quarter stood at approximately $693 million, marking a 3.9% increase from the previous year. For the full year, net sales rose to $2.583 billion, a slight rise of 0.7% from the previous year. This growth was primarily attributed to the Clinical Diagnostics segment, which experienced an 8.4% increase in sales in Q4 driven by higher demand for quality control and blood typing products. A significant challenge was the gross margin which declined, reaching 49.8% on a GAAP basis in Q4, compared to 51.2% in the prior year. For the entire year, the non-GAAP gross margin declined to 53.3% from 55%. These declines were influenced by increased supply chain costs and procurement issues, although these are deemed operational rather than structural problems.